title: [Aspirin vs ticlid and their combination in patients with acute myocardial infarction].
abstract: ADP-induced platelet aggregation was studied in 28 patients with myocardial infarction randomized, at admission, into three groups. Conventional therapy with heparin and antianginal drugs was combined with aspirin (250 mg/day, n = 9), tiklid (500 mg/day, n = 9), tiklid (500 mg/day) + aspirin (250 mg/day, n = 10) in group 1, 2 and 3, respectively. Tiklid diminished platelet aggregation more effectively than aspirin on the disease day 7 and 21. Tiklid + aspirin combination suppresses platelet aggregation more than monotherapy with either of the drugs, provides insignificant attenuation of postinfarction angina but is associated with a high risk of hemorrhagic complications.
authors.forename: E V
authors.initials: EV
authors.lastname: Vyshlov
authors.forename: E V
authors.initials: EV
authors.lastname: Panfilova
authors.forename: V A
authors.initials: VA
authors.lastname: Markov
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013988:Ticlopidine / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin